CD274 and non-small cell lung carcinoma: Previous studies have paid little attention to markers of immunotherapy benefits in PD-L1 positive patients, and we have developed and validated a non-invasive and clinically applicable model that combines clinical factors and gene mutation characteristics before treatment to predict the treatment benefits of ICIs immunotherapy in advanced NSCLC PD-L1 positive patients.